It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aim. This research aimed to enhance the methodology for efficiently evaluating CK2 inhibitors using capillary electrophoresis and validate the techniques with the CK2 inhibitor FNH79. Additionally, the study included the assessment of a novel potential inhibitor, the aurone derivative BFO21, using the optimized protocol. Methods. The research was conducted with the capillary electrophoresis method, and 150 mM orthophosphoric acid (pH 1.2) as a background electrolyte. Conversion of enzymatic reaction was calculated as the ratio of the phosphorylated product peak area to the total peak area of both substrate and product. Results. The optimal testing conditions were determined, involving 50 units of the enzyme per 50 μl of the reaction mixture, an initial peptide substrate concentration of 100 μM, and an incubation time of 40 minutes. The initial concentration of ATP was 100 μM. FNH79 demonstrated IC50 and Ki values of 94 nM and 4.5 nM, respectively. The new aurone compound BFO21 exhibited IC50 and Ki values of 44 nM and 2.1 nM, respectively. Conclusions. Under optimized testing conditions, the activity values for the FNH79 inhibitor strongly matched previously published results. Additionally, the activity values of the BFO21 inhibitor revealed its significant potential as the CK2 inhibitor.